跳至主要内容
临床试验/NCT03701074
NCT03701074终止2 期

Single Center, Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Safety and Efficacy of Acetaminophen in Preterm Infants Used in Combination With Ibuprofen for Closure of the Ductus Arteriosus

University of South Alabama1 个研究点 分布在 1 个国家目标入组 1 人开始时间: 2018年12月15日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
终止
入组人数
1
试验地点
1
主要终点
Ductus Arteriosus Closure/Constriction Rate

研究概览

简要总结

The purpose of the present study is to determine whether treatment of hemodynamically significant patent ductus arteriosus with a combined therapy of intravenous Ibuprofen and oral acetaminophen has higher success rate in closing the ductus arteriosus than a standard treatment strategy of using intravenous ibuprofen alone among preterm infants.

详细描述

The primary objectives of the study are to confirm the safety of oral acetaminophen in extremely low birth infants, given concomitantly with intravenous ibuprofen and also to determine its efficacy in significantly increasing the rates of ductal closure when compared to only intravenous ibuprofen therapy. Hence primary outcome variable include patent ductus arteriosus closure success rate, based on the 2-D transthoracic echocardiographic evidence.

This study is a single center, randomized, double blinded, placebo controlled trial. Preterm infants with gestational age of with a gestational age ≤27 6/7 weeks by the best obstetric estimate are eligible for enrollment.

For randomization, the study population will be stratified to two subgroups based on gestational age (GA ≤24 weeks and > 25 weeks). Randomization will occur by using computer generated random sequence, using a 4-block design, with 1:1 parallel allocation. Allocations include treatment and control arm. Treatment arm will receive combination of intravenous ibuprofen and oral acetaminophen, while control arm will receive intravenous Ibuprofen and oral placebo.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
5 Days 至 21 Days(Child)
性别
All
接受健康志愿者

入选标准

  • Preterm infant ≤27 6/7
  • Written parental consent is obtained
  • Infant requires respiratory support
  • diagnosis of a persistent patent ductus arteriosus after 5 days of age, (defined as at least two of the following:
  • Ductus size ≥ 1.5 mm
  • Maximum flow velocity through the ductus ≤ 2 m/s
  • Left atrium to aorta ratio ≥ 1.4
  • Wide pulse pressure
  • B-type natriuretic peptide (BNP)
  • Attending neonatologist made decision to treat patent ductus arteriosus

排除标准

  • No parental consent
  • Infants > 21days of postnatal age
  • Congenital anomalies such as cardiac or multiple anomalies
  • Infection (e.g., septicemia, pneumonia)
  • Bleeding disorder or platelet count< 50,000/ml
  • Acute kidney injury (AKI)defined as oliguria (urine output< 0.5 ml/kg/hr for 16hrs) and/or serum creatinine > 1.5 mg/dl
  • Elevated liver enzymes (>2 fold from upper normal limits)
  • Pulmonary hypertension or right to left shunt through the ductus arteriosus
  • Diagnosis of necrotizing enterocolitis
  • Unable to tolerate oral medications at the time of enrollment.

研究组 & 干预措施

ibuprofen and acetaminophen arm (intervention arm)

Experimental

ibuprofen and acetaminophen will be administered concomitantly. Ibuprofen will be administered through intravenous route. The dose of ibuprofen will be the standard dosing regimen used in our unit: dosing based on the postnatal age. For Infants > 108 h of postnatal age: 18 mg/kg/dose loading dose followed by 9 mg/kg/dose, two doses at q24 intervals, started 24 h after the loading dose. Acetaminophen will be administered as oral formulation. Acetaminophen is given at a dose of 15 mg/Kg/dose, q 6 hours, for 3 days (total of 12 doses).

干预措施: Ibuprofen and acetaminophen (Drug)

ibuprofen and placebo arm (control arm)

Active Comparator

ibuprofen and acetaminophen will be administered concomitantly. Ibuprofen will be administered through intravenous route. The dose of ibuprofen will be the standard dosing regimen used in our unit: dosing based on the postnatal age. For Infants > 108 h of postnatal age: 18 mg/kg/dose loading dose followed by 9 mg/kg/dose, two doses at q24 intervals, started 24 h after the loading dose. Placebo will be sterile water, with similar volume and color as acetaminophen, will be given through the oro-gastric tube, for three days at 6 h intervals.

干预措施: Ibuprofen and placebo (Drug)

结局指标

主要结局

Ductus Arteriosus Closure/Constriction Rate

时间窗: 24-48 hours after the completion of study intervention

Ductal closure/constriction rate as defined based on the echocardiographic findings. Ductal closure/constriction will be defined as the complete closure of ductus or ductal diameter \<1 mm

次要结局

  • Rate of Surgical Ligation of PDA(from randomization until discharge/40 weeks post menstrual age)
  • Ventilatory Settings Before and After the Study Intervention(24-48 hours after the completion of study intervention)
  • Echocardiographic Patent Ductus Arteriosus Parameters Before and After the Study Intervention(24-48 hours after the completion of study intervention)
  • Rate of Liver Injury(24-48 hours after the completion of study intervention)
  • Rate of Renal Injury(24-48 hours after the completion of study intervention)
  • Rate of Periventricular Leukomalacia(from randomization until discharge/40 weeks post menstrual age)
  • Rate of Hematological Adverse Events(24-48 hours after the completion of study intervention)
  • Total Number of Days of Mechanical Ventilation(from randomization until discharge/40 weeks post menstrual age)
  • Total Number of Days of Need for Supplemental Oxygen(from randomization until discharge/40 weeks post menstrual age)
  • Rate of Persistence of Ductus-needing Pharmacological Treatment(from randomization until discharge/40 weeks post menstrual age)
  • Rate of Bronchopulmonary Dysplasia(at 36 weeks post menstrual age)
  • Percentage of Infants Requiring Home Oxygen Therapy(at discharge/40 weeks post menstrual age)
  • Death Before Discharge(until discharge/40 weeks post menstrual age)
  • Time to Achieve Full Enteral Feeding(from birth until discharge/40 weeks post menstrual age)
  • Days on Total Parenteral Nutrition(from birth until discharge/40 weeks post menstrual age)
  • Retinopathy of Prematurity(from birth until discharge/40 weeks post menstrual age)
  • Rate of Spontaneous Intestinal Perforation(from randomization until discharge/40 weeks post menstrual age)
  • Rate of Gastrointestinal Hemorrhage(from randomization until discharge/40 weeks post menstrual age)
  • Rate of Late Onset Sepsis(from randomization until discharge/40 weeks post menstrual age)
  • Duration of Noninvasive Ventilation(from randomization until discharge/40 weeks post menstrual age)
  • Rate of Necrotizing Enterocolitis(from randomization until discharge/40 weeks post menstrual age)
  • Length of Hospital Stay(from birth until discharge/40 weeks post menstrual age)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Ramachandra Bhat

Assistant Professor

University of South Alabama

研究点 (1)

Loading locations...

相似试验

已完成
3 期
A Study Comparing Blood Flow and Clinical and Safety Effects of the Addition of Natrecor (Nesiritide), Placebo or Intravenous Nitroglycerin to Standard Care for the Treatment of Worsening Congestive Heart Failure.Symptomatic Decompensated Congestive Heart FailureCongestive Heart Failure in Acute Coronary Syndrome
NCT00270374Scios, Inc.498
进行中(未招募)
不适用
Clinical investigation into efficacy, hemodynamics and tolerability of simvastatin vs placebo in patients with pulmonary arterial hypertension(Shorttitle: SIPHT)Double-blind, randomized, prospective Phase III-b study for 6 months with adjusting doses of simvastatin (40/80 mg daily) or placebo followed by an open-label period with a final dose of simvastatin 80 mg daily for another 6 months - SIPHTModified NYHA class II or III patients with Pulmonary Hypertension (PH), ICD: 416.9MedDRA version: 8.1Level: LLTClassification code 10020787Term: Hypertension pulmonary
EUCTR2005-004863-41-DEDept. of Internal Medicine II, University Hospital Giessen40
已完成
不适用
Clinical investigation into efficacy, haemodynamics and tolerability of simvastatin versus placebo in patients with pulmonary arterial hypertensioPulmonary hypertensionCirculatory SystemOther pulmonary heart diseases
ISRCTN27178415niversity Hospital Giessen (Germany)40
已完成
不适用
Effectiveness of A Hemodynamic-Guided Treatment Strategy to Improve Blood Pressure ControlHypertension
NCT04715698Peking University People's Hospital102
已完成
不适用
Compare in Blood pressure and pulse rate in heart surgery patients using two drugs
CTRI/2019/02/017839Sri Ramakrishna hospital60
Randomized Controlled Trial to Evaluate the Safety... | 临床试验